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Subjective and Objective Measures of Dryness
Symptoms in Primary Sj€ogren’s Syndrome:
Capturing the Discrepancy
ORIANA M. BEZZINA,1 PETER GALLAGHER,1 SHERYL MITCHELL,2 SIMON J. BOWMAN,3
BRIDGET GRIFFITHS,2 VICTORIA HINDMARSH,2 BEN HARGREAVES,2 ELIZABETH J. PRICE,4 COLIN T.
PEASE,5 PAUL EMERY,5 PETER LANYON,6 MICHELE BOMBARDIERI,7 NURHAN SUTCLIFFE,8
COSTANTINO PITZALIS,7 JOHN HUNTER,9 MONICA GUPTA,9 JOHN MCLAREN,10 ANNE M. COOPER,11
MARIAN REGAN,12 IAN P. GILES,13 DAVID A. ISENBERG,13 VADIVELU SARAVANAN,14 DAVID
COADY,15 BHASKAR DASGUPTA,16 NEIL J. MCHUGH,17 STEVEN A. YOUNG-MIN,18 ROBERT J. MOOTS,19
NAGUI GENDI,20 MOHAMMED AKIL,21 KIRSTEN MACKAY,22 W. FAI NG,23 LUCY J. ROBINSON,1 AND THE
UK PRIMARY SJ€OGREN’S SYNDROME REGISTRY
Objective. To develop a novel method for capturing the discrepancy between objective tests and subjective dryness
symptoms (a sensitivity scale) and to explore predictors of dryness sensitivity.
Methods. Archive data from the UK Primary Sj€ogrenʼs Syndrome Registry (n = 688) were used. Patients were classi-
fied on a scale from 5 (stoical) to +5 (sensitive) depending on the degree of discrepancy between their objective and
subjective symptoms classes. Sensitivity scores were correlated with demographic variables, disease-related factors,
and symptoms of pain, fatigue, anxiety, and depression.
Results. Patients were on average relatively stoical for both types of dryness symptoms (mean  SD ocular dryness
0.42  2.2 and 1.24  1.6 oral dryness). Twenty-seven percent of patients were classified as sensitive to ocular dry-
ness and 9% to oral dryness. Hierarchical regression analyses identified the strongest predictor of ocular dryness sen-
sitivity to be self-reported pain and that of oral dryness sensitivity to be self-reported fatigue.
Conclusion. Ocular and oral dryness sensitivity can be classified on a continuous scale. The 2 symptom types are pre-
dicted by different variables. A large number of factors remain to be explored that may impact symptom sensitivity in
primary Sj€ogrenʼs syndrome, and the proposed method could be used to identify relatively sensitive and stoical
patients for future studies.
INTRODUCTION
Primary Sj€ogren’s syndrome (SS) is an autoimmune dis-
order of unknown etiology that is characterized by dry
eyes and dry mouth and is associated with extraglandu-
lar systemic symptoms such as fatigue, pain (myalgia
and polyarthralgia), and autonomic dysfunction (1). It
has an estimated prevalence of 0.01–0.09% (2) and is
more common in women (9:1 female:male ratio) (3). The
condition has a marked negative impact on health-related
quality of life and social functioning (4).
The medications used to improve extraglandular symp-
toms are less effective in treating sicca symptoms (5). An
important factor for knowledge and treatment is the
weak association between the results of objective clinical
tests of tear or saliva production and the severity of
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self-reported dryness symptoms. This is reflected in the
current America European Consensus Group (AECG)
classification criteria, which dictate that a primary SS
diagnosis be made when individuals fulfill 4 or more of
the established criteria, which include both subjective
and objective items (6). Understanding the discrepancy
between objective and subjective findings may be of
importance for improving research into the condition.
Several studies have indicated weak correlations
between objective and subjective indices of ocular dryness
(7–15). Although the majority of these studies found that
greater subjective symptoms are associated with greater
objective severity, 2 observed that lower subjective symp-
toms were associated with greater objective severity (7,15),
which may be related to the reduced sensation resulting
from greater damage to the eye (7). In contrast, the relation-
ship between subjective and objective oral dryness mea-
sures seems to be stronger (16–21), although there are
some individuals with subjective xerostomia who show
no objective salivary gland dysfunction (17).
Discrepancies between objective and subjective symp-
toms create a number of dilemmas for clinicians. For
example, patients may not receive optimal treatment
(those with abnormal test results but few subjective symp-
toms may be undertreated, whereas those with normal test
results but high subjective symptoms may receive inter-
ventions that are unlikely to help). Furthermore, it
becomes difficult to interpret (lack of) response to treat-
ment, which could be particularly important in clinical
trials of novel therapeutic agents. It is therefore important
to explore this relationship in greater depth. The path
from pathologic change in tissues to perceived distressing
symptoms is complex and dependent on a number of fac-
tors relating to both the severity of the underlying disease
and to concomitant psychosocial factors such as low mood
and anxiety (22–26). Developing a method to differentiate
patients on the basis of their sensitivity to symptoms
could aid research on the factors that contribute to vari-
ability in the distress and disability caused by primary SS
and ultimately could contribute to the stratification of
patients for particular management pathways.
The present study develops a novel method to define
the degree of concordance/discrepancy between objective
and subjective findings. This will be used to investigate
the relationship between subjective symptoms and objec-
tive measures of dry eyes and mouth in people with pri-
mary SS to identify factors associated with symptom
sensitivity.
PATIENTS AND METHODS
Participants. The present study uses archive data from
688 patients in the United Kingdom Primary Sj€ogrenʼs
Syndrome Registry database (www.sjogrensregistry.org),
who were recruited from 30 hospital sites from August
2009 to March 2012 (for full details, see Ng et al [27]).
All patients fulfilled the AECG classification criteria (6).
Patients gave written informed consent to participate,
and National Health Service ethics approval was granted
for this study from the North West–Haydock National
Research Ethics Service committee.
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Significance & Innovations
• This study outlines a novel method for defining
concordance between objective signs and subjec-
tive symptoms that is independent of units of
measurement.
• The method can identify both stoical individuals
(high objective signs and low subjective symp-
toms) and sensitive individuals (low objective
signs and high subjective symptoms).
• We explored factors predicting symptom sensitiv-
ity and found that pain and fatigue symptoms
were the biggest predictors of sensitivity to ocular
and oral dryness, respectively.
• Much of the variance in symptom sensitivity
remains unexplained; this method could be used in
future studies to identify sensitive individuals and
investigate a larger number of predictive factors (in-
cluding further biologic and psychologic measures).
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Patient- and clinician-reported measures. Subjective
symptoms were assessed using the European League
Against Rheumatism (EULAR) Sj€ogren’s Syndrome
Patient-Reported Index (ESSPRI) sicca scores. This is a
validated self-report measure of symptoms of ocular and
oral dryness (28,29). Patients rated their symptoms over
the past 2 weeks on a 0–10 scale, where 10 = maximum
imaginable dryness. In addition, there were also items
that measured subjective fatigue, mental fatigue, and
pain. Patients also self-reported their medication use and
comorbidities.
The EuroQol 5-dimension 3-level scale (30) was used
to measure quality of life. It includes a simple visual
analog scale (VAS) and a time tradeoff value, and lower
values indicate better quality of life. Depression and
anxiety were measured using the Hospital Anxiety and
Depression Scale (31). The EULAR Sj€ogrenʼs Syndrome
Disease Activity Index (29,32) and Disease Damage
Index (ESSDDI) (33) were used to assess the extent of
systemic disease activity and damage, respectively.
Ocular dryness. For the Schirmer I test, a sterile strip
of filter paper was inserted inside the patient’s lower
eyelid for 5 minutes, after which the level of wetting was
measured using a standardized ruler. The average result
of both eyes was then calculated. Participants were
asked not to use eyedrops for 2 hours prior to testing.
Lower scores indicate abnormal tear production and a
score of ≤5 mm/5 minutes is considered severe by AECG
criteria (6).
Oral dryness. To test unstimulated salivary flow
(USF), the patient was required to spit saliva into a
graduated test tube every minute. This was conducted at
normal room temperature and humidity, and participants
were asked not to eat/drink/smoke for at least 2 hours
beforehand. According to AECG criteria, a quantity of
≤1.5 ml collected over 15 minutes indicates impaired
saliva secretion (6).
Defining discordance. The present study used a
modified discordance measure that was based on
Delbaere et al (2010) (34). Subjective symptom severity
and objective test result severity for both ocular and oral
dryness were split into classes. Patients’ subjective
ocular and oral dryness severities (based on ESSPRI item
scores) were grouped into asymptomatic (scoring 0) and
symptomatic groups (5 equal classes; see Figure 1).
Objective test result severities were grouped into the
same number of classes. As no formal severity “grading”
is available for either the Schirmer’s test or USF results,
reasonable severity “grading” cutoffs, supported by the
expert consensus of a consulting rheumatologist (WFN),
were established for the purposes of this study, and test
results were grouped into equal severity classes, as
shown in Figure 1. The severe-class cutoffs, for both the
Schirmer and USF tests, were set as close as possible to
the diagnostic cutoffs used in the AECG criteria.
The subjective severity classes for ocular and oral dry-
ness were then cross-tabulated with the corresponding
objective severity class in order to identify each patient’s
degree of sensitivity for ocular and oral dryness. This was
done using the sensitivity grid shown in Figure 1. The
disparity between subjective symptoms and objective test
results was given an arbitrary value and conceptualized
on a continuous sensitivity scale (Figure 2). On the scale,
a value of 0 signifies full concordance, with negative val-
ues indicating increasing stoicism and positive values
indicating increasing sensitivity. Patients were grouped
into sensitive (positive sensitivity score), accurate (score
of 0), and stoical (negative sensitivity score) groups.
Analysis. Analyses were performed using IBM SPSS
software, version 21. Pairwise deletions for missing data
were employed. One-way analysis of variance with post
hoc least significant difference tests were used to compare
groups, using an alpha level of 0.05. Proportion data
Objective Test Results Normal Mild Moderate Severe
Schirmer I Test (mm/5min) >14.5
(n=109; 16%)
11.5-14.5
(n=40; 6%)
8.5-11.5
(n=37; 5%)
5.5-8.5
(n=67; 10%)
2.5-5.5
(n=120; 17%)
<2.5
(n=315; 46%)
Unstimulated Salivary Flow (ml/15min) >5
(n=26; 4%)
4-5
(n=8; 1%)
3-4
(n=9; 1%)
2-3
(n=42; 6%)
1-2
(n=74; 11%)
<1
(n=529; 77%)
Su
bj
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0: Asymptomatic 0 -1 -2 -3 -4 -5
1-2: Mild 1 0 -1 -2 -3 -4
3-4 2 1 0 -1 -2 -3
5-6: Moderate 3 2 1 0 -1 -2
7-8 4 3 2 1 0 -1
9-10: Severe 5 4 3 2 1 0
Figure 1. Severity classification groups for objective results and subjective symptoms and the grid used to derive the sensitivity score.
For example, an individual with severe objective test results (Schirmer <2.5 or saliva flow <1) but subjectively rating themselves 1
(mild) would have a discrepancy classification of 4, thereby lying at the stoical side of the distribution. An individual subjectively
reporting their symptoms 9 (severe) while having a normal objective test results would score +5, at the most sensitive side of the
distribution.
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between groups were compared using chi-square tests,
with any significant overall difference followed up with
pairwise comparisons with a Bonferroni-adjusted P value
equaling 0.05 / 3 = 0.017. Bivariate Spearman’s
correlations were used to explore the relationships
between objective and subjective measures and between
sensitivity and demographic variables, disease- and
treatment-related factors, and self- and clinician-rated
symptoms. The strength of correlations was compared
using Fisher’s r-to-z transformation. Linear stepwise
hierarchical multiple regression was used to explore
predictors of sensitivity. Variables were entered stepwise
in the following sequence of blocks: first, demographics
and disease factors (age, sex, symptom duration, ESSDDI
score, number of comorbidities, number of medications,
number of xerogenic medications, and use of a lachrymal/
saliva substitute) and, second, other symptoms and
quality of life (fatigue, mental fatigue, pain, anxiety,
depression, and VAS assessing quality of life). The criteria
for entry into the model was a P value less than 0.05, and
for exit, a P value greater than 0.1. Separate regressions
were run for ocular and oral sensitivity. Only the results
for the variables appearing in the final model are reported.
RESULTS
Participant characteristics and scores on the measures
are shown in Table 1. The majority of the sample was
female (n = 651, 95%). Lachrymal and saliva substitutes
were used by 544 participants (79.1%) and 305 partici-
pants (44.3%), respectively. There were 295 participants
(42.9%) who were taking at least 1 xerogenic medication.
Subjective versus objective symptoms. A weak but
significant correlation (r = 0.13, P = 0.001) was found
between ocular dryness and Schirmer test results. A
moderate correlation (r = 0.31, P < 0.001) was found
between oral dryness and USF test results. The directions
of the relationships indicate that greater symptom severity
was associated with lower tear and saliva production.
Objective and subjective results were significantly more
strongly correlated for oral dryness than for ocular dryness
(Z = 3.47, P < 0.001).
Symptom severity and sensitivity. Figure 1 shows the
proportion of patients falling into the 6 severity classes on
each of the objective measures. Forty-six percent of
patients were in the most severe range for the Schirmer
test and 77% for USF, indicating that markedly reduced
saliva production was more common than markedly
reduced tear production. In what we defined as the normal
range for the Schirmer test, there were 16% of patients,
compared with only 4% for USF. Cross-tabulating ocular
and oral severity gradings showed that only 8 people
(1.2%) were in the normal range on both measures,
whereas 268 (39.4%) were in the most severe classification
for both. In this sample, a high proportion of patients had
severe symptoms on at least 1 objective test measure.
A level of discordance (i.e., a sensitivity score other than
0) was observed in 80.9% and 73.7% of the participants for
ocular and oral dryness, respectively. The mean  SD ocu-
lar sensitivity was found to be 0.42  2.2 and 1.24  1.6
for oral sensitivity, indicating that, on average, patients
were relatively stoical for both types of dryness symptoms.
Fewer patients scored in the sensitive range (≥+1) for oral
dryness (n = 59, 8.7%) than for ocular dryness (n = 178,
26.8%). This is partly related to differences in the severity
of objective results; the majority of patients had severely
reduced saliva production and therefore could not score in
the sensitive range. Sensitivity for ocular and oral dryness
were positively correlated (r = 0.35, P < 0.001), indicating
that higher sensitivity for ocular dryness was associated
with higher sensitivity for oral dryness.
Factors influencing ocular and oral dryness
sensitivity. Table 2 shows means by group for selected
factors that might contribute to symptom sensitivity. The
Figure 2. The sensitivity scale used in the study.
Table 1. Patient characteristics and variables*
No. Mean  SD
Demographics and illness factors
Age, years 688 58.0  12.5
Disease duration, months 661 80.1  71.5
Symptom duration, months 686 152.4  118.8
Symptom/diagnosis gap, months 659 72.7  98.6
No. comorbidities 688 3.6  2.5
No. medications 688 5.7  4.1
Patient-rated measures
Ocular dryness (range 0–10) 681 5.6  2.8
Oral dryness (range 0–10) 681 6.0  2.9
Fatigue (range 0–10) 681 5.5  2.7
Mental fatigue (range 0–10) 680 3.9  2.8
Pain (range 0–10) 680 4.5  3.0
QoL, time tradeoff (range 1.0
to 1.0)
671 0.6  0.3
QoL, VAS (range 0–100) 664 60.3  21.4
HADS anxiety (range 0–21) 666 8.0  4.6
HADS depression (range 0–21) 667 6.0  4.0
Clinician-rated measures
ESSDAI (range 0–123) 687 4.8  4.9
ESSDDI (range 0–10) 688 2.5  1.9
Objective tests
Schirmer’s test (mm/5 min) 671 6.2  7.6
Unstimulated salivary flow
(ml/15 min)
688 0.9  1.9
Sensitivity
Ocular sensitivity (range 5 to +5) 681 0.42  2.2
Oral sensitivity (range 5 to +5) 681 1.24  1.6
* QoL = quality of life; VAS = visual analog scale; HADS = Hospital
Anxiety and Depression Scale; ESSDAI = European League Against
Rheumatism (EULAR) Sj€ogren’s Sydrome Disease Activity Index;
ESSDDI = EULAR Sj€ogren’s Syndrome Disease Damage Index.
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pattern was very similar for both ocular and oral
sensitivity. There were no significant differences in total
number of comorbidities, but oral-stoical patients were
taking significantly fewer medications (of any type) than
accurate patients (P = 0.002). For both types of symptom
sensitivity, stoical patients showed significantly less
anxiety and depression and reported significantly higher
quality of life than both sensitive and accurate patients (P
< 0.05 for all). There were no significant differences in
anxiety and depression between the sensitive group and
the accurate group (P > 0.05 for all). There was a
significant difference between the groups in the self-
reported presence of functional conditions, with the
sensitive group reporting a significantly higher incidence
of both fibromyalgia and irritable bowel syndrome than
the stoical group (P < 0.017 for all). Oral-sensitive patients
reported a significantly higher incidence of irritable bowel
syndrome than accurate patients (P = 0.003), but otherwise
there were no further significant differences between the
sensitive and accurate groups. There were no significant
differences between the groups in the proportion of those
with any Diagnostic and Statistical Manual of Mental
Disorders–defined or International Classification of
Diseases–defined mental illness (P > 0.05 for all).
Spearman’s bivariate correlations were used to explore
other factors associated with symptom sensitivity, and
the results for both ocular and oral dryness sensitivity
are shown in Table 3. Ocular sensitivity was weakly pos-
itively correlated with number of medications and
weakly negatively correlated with age, suggesting that
patients taking fewer medications and older patients
were more stoical. Oral sensitivity was weakly positively
correlated with number of comorbidities and number of
medications, suggesting that those with fewer comorbidi-
ties and taking fewer medications were more stoical.
Both types of sensitivity were moderately strongly posi-
tively correlated with patient-rated symptoms, including
fatigue, mental fatigue, pain, anxiety, and depression.
The direction of the correlations indicated that those
with higher levels of these symptoms were more sensi-
tive. Both types of sensitivity were negatively correlated
with quality of life, indicating that those with poorer
quality of life had higher sensitivity scores.
Relationship between treatment and symptom
sensitivity. Patients in the different sensitivity classes
receiving treatment were examined in order to explore
relationships between symptom sensitivity and treatment
received (Table 2). Ocular-stoical patients were
significantly less likely to be receiving a medication
known to cause dryness than sensitive patients (P =
0.004), and while there was an overall group difference
for oral sensitivity, post hoc tests did not show any
significant differences between the groups. There were
no significant differences between the groups in the use
of at least 1 symptomatic treatment for dryness or
pilocarpine (P > 0.218 for all). However, oral stoics were
significantly less likely to be using a saliva substitute
(40.1%) than accurate patients (56.4%; P < 0.001), and
there was no significant difference between stoical and
sensitive patients (43.1%; P = 0.660). Similarly for
ocular sensitivity, ocular stoics were significantly less
likely than accurate patients to have received the more
invasive treatments of punctal plugging or cauterization
(18.8% versus 33.8%; P = 0.012), and there were no
differences in ocular-sensitive patients (22.0%; P =
0.367). Ocular-sensitive patients were significantly less
likely to be using a lachrymal substitute than both
the accurate and stoical patients (71.5% versus 83.1%
and 82.6%, respectively; P = 0.016 and P = 0.002,
respectively).
Regression analysis. Ocular dryness. The final model
contained 6 predictor variables and was statistically
significant (F6,628 = 21.8, P < 0.001), explaining 16.5% of
the variance in sensitivity (Table 4). The statistically
significant predictors in the final model were age, ESSDDI
score, pain, fatigue, and mental fatigue. Pain explained
the largest additional variance (10%) of all the predictors,
and fatigue was the next highest (2.3%). Age and ESSDDI
score were both negatively related to sensitivity,
indicating that older patients and those with greater
disease damage tended to be less sensitive.
Oral dryness. The final model contained 6 predictor
variables and was statistically significant (F6,628 = 24.1,
P < 0.001) explaining 17.9% of the variance in sensitivity
(Table 4). The statistically significant predictors in the
final model were use of a saliva substitute, fatigue, and
depression, all of which were positively associated with
greater sensitivity. Level of fatigue explained the largest
additional variance (11.7%), indicating that those with
higher fatigue tended to be more sensitive.
Table 3. Spearman’s (rs) bivariate correlations
between ocular and oral sensitivity*
Ocular
sensitivity
Oral
sensitivity
Demographic and illness factors
Age 0.11† 0.02
Disease duration 0.02 0.07
Symptom duration 0.00 0.03
No. comorbidities 0.07 0.11‡
No. medications 0.10‡ 0.12‡
Patient-rated measures
Fatigue 0.38† 0.39†
Mental fatigue 0.33† 0.30†
Pain 0.33† 0.29†
Quality of life, time tradeoff 0.25† 0.24†
Quality of life, VAS 0.21† 0.28†
HADS anxiety 0.20† 0.26†
HADS depression 0.22† 0.30†
Clinician-rated measures
ESSDAI 0.02 0.03
ESSDDI 0.07 0.05
Oral sensitivity 0.35† –
* VAS = visual analog scale; HADS = Hospital Anxiety and
Depression Scale; ESSDAI = European League Against Rheumatism
(EULAR) Sj€ogren’s Syndrome Disease Activity Index; ESSDDI =
EULAR Sj€ogren’s Syndrome Disease Damage Index.
† P ≤ 0.001.
‡ P from 0.001 to ≤ 0.01.
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DISCUSSION
As in other studies, subjective dryness symptoms and
objective test results were only weakly correlated in
patients with primary SS. A novel method for quantify-
ing the discrepancy between subjective and objective
symptoms was devised, as an ordinal scale of symptom
sensitivity, ranging from stoical (self-reported dryness at
a relatively low level compared to objective findings) to
accurate to sensitive (self-reported dryness at a rela-
tively high level compared to objective findings). The
majority of patients had a relatively stoical presentation.
A significant moderate association was observed
between ocular and oral dryness sensitivity, indicating
that those who tended to be sensitive to ocular dryness
also tended to be sensitive to oral dryness. Comparisons
of sensitive, stoical, and accurate patients showed that
stoical patients had lower depression and anxiety scores
than the other groups, but they were also less likely to
have received some treatments than accurate patients
(saliva substitute and punctal plugging or cauterization).
Sensitive patients were not more likely to receive higher
levels of intervention than accurate or stoical patients,
but a greater proportion of them reported functional
conditions (fibromyalgia and irritable bowel syndrome).
In regression analyses, symptom sensitivity was pre-
dicted by a variety of factors, but pain (ocular sensitiv-
ity) and fatigue (oral sensitivity) explained the most
variance.
As found in other studies, the relationship between
subjective and objective measures was weaker for ocular
dryness than for oral dryness (35–37). Ocular dryness
sensitivity was predicted by greater pain and fatigue,
whereas age and disease damage were significant nega-
tive predictors, suggesting that older patients and those
with more severe disease are relatively more stoical.
Adatia et al (7) suggested that symptom perception may
be diminished by reduced corneal sensation due to more
severe illness, which may explain the negative relation-
ship with disease damage. This may be part of the expla-
nation for why subjective and objective ocular dryness
measures correlate relatively more weakly; a straightfor-
ward, linear relationship between severity of disease and
severity of subjective symptoms would not be expected.
Additionally, there were fewer patients whose objective
test results fell in the severe range for tear production
(46%) compared to saliva production (77%), and 16%
had objectively normal tear production (compared to
only 4% for saliva production), leaving more scope to
identify ocular patients as sensitive. The symptom of dry
eye is less well-defined than dry mouth and may be used
to refer to a myriad of ocular sensations, including burn-
ing pain, grittiness, and tired or heavy eyes. This intro-
duces heterogeneity in patients, in terms of what they
mean when they report having dry eyes, and not all of
the experienced sensations can be expected to relate to
tear production. As “dry eye” often refers to painful sen-
sations in the eye, this may explain why self-reported
pain was the greatest predictor of ocular sensitivity (but
was not a significant predictor of oral sensitivity).
In contrast, sensitivity to oral dryness symptoms was
most strongly associated with global fatigue, followed by
use of a saliva substitute and number of comorbidities. It
was not related to disease severity or pain. This suggests
that different processes are related to symptom sensitiv-
ity to different symptoms. The overall proportion of
variance explained in both regression models (i.e., 16.5–
17.9%) indicates that there are explanatory factors that
were not included in the present study, which should be
explored in future studies. Biologic factors relating to
the composition of the tears or saliva may be relevant.
Xerostomia can be affected by saliva composition (38),
Table 4. Stepwise hierarchical regression summary for ocular dryness sensitivity and oral
dryness sensitivity*
Model Adj. R2 (%) DR2 (%) Standardized b Test-statistic P
Ocular dryness sensitivity
Overall model 16.5 – – F6,628 = 21.8 < 0.001†
Age 1.3 0.09 t634 = 2.39 0.017‡
No. medications 1.9 0.01 t634 = 0.25 0.802
ESSDAI 0.5 0.08 t634 = 2.23 0.026‡
Pain 10.0 0.19 t634 = 3.89 < 0.001†
Fatigue 2.3 0.16 t634 = 2.95 0.003†
Mental fatigue 0.5 0.11 t634 = 2.14 0.033‡
Oral dryness sensitivity
Overall model 17.9 – – F6,628 = 24.1 < 0.001†
Use of saliva substitute – 2.9 0.15 t634 = 3.99 < 0.001†
No. comorbidities – 1.3 0.02 t634 = 0.43 0.667
Age – 0.6 0.01 t634 = 0.21 0.831
Xerogenic medications – 0.5 0.01 t634 = 0.24 0.812
Fatigue – 11.7 0.30 t634 = 6.88 < 0.001†
Depression – 0.9 0.13 t634 = 2.91 0.004†
* Adj. = adjusted; ESSDAI = European League Against Rheumatism Sj€ogren’s Sydrome Disease Activity Index.
† P ≤ 0.001.
‡ P > 0.001 and ≤0.05.
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and multiple factors, such as lachrymal secretion, corneal
damage, tear film stability, and the chemical properties of
tears all jointly affect the perception of ocular dryness
(39). Relatively sensitive individuals could be targeted in
future research to identify biologic markers in tears or
saliva that may affect perceived dryness.
Psychologic models of symptom perception propose a
large number of factors that may impact on whether
someone notices a symptom (26) and could be of rele-
vance to measure in PSS. Trait characteristics such as
neuroticism, alexithymia (the ease with which one iden-
tifies emotions), and distress tolerance may play a role
(40,41). It has been shown that catastrophization (a man-
ner of thinking that exaggerates worries and amplifies
negative consequences) (42) is highly predictive of pain
severity in patients with primary SS (43). Similarly,
greater body-focused attention may contribute to symp-
tom-noticing (44), and somatosensory amplification (a
heightened responsiveness to sensory stimulation) has
been shown to contribute to the symptoms of many rheu-
matic conditions (41). Geisser et al (45) found that ampli-
fication in chronic fatigue syndrome and fibromyalgia
was related to higher clinical pain and larger numbers of
comorbid somatic symptoms and, consistent with this
finding, we identified a greater proportion of patients
with fibromyalgia in the sensitive groups. Anxiety and
depression have also been shown to be significantly
related to greater sensitivity. In a population-based study
by Anttila et al (22), participants with subjective dry
mouth had depressive symptoms in significantly higher
frequencies. Similarly, Kim et al (24) concluded that
depression was associated with dry eye symptoms in
participants with normal Schirmer test results. Addition-
ally, social, contextual, cultural, and interpersonal fac-
tors likely also contribute to how and whether patients
openly discuss their symptoms with their doctor, making
it difficult to determine, particularly for stoical patients,
whether they do not experience distressing symptoms or
they simply do not report them.
The strengths of this study include the large sample of
primary SS patients and the novel method for defining
sensitivity, which allowed potential associated variables
to be investigated. However, there are a number of limita-
tions. First, self-report methods are prone to response
bias, such as demand characteristics bias, social desirabil-
ity bias, and recall bias (46). Furthermore, when complet-
ing the self-report measure, participants judged the
severity of their sicca symptoms against their own stan-
dards; however, the severity of objective measures is
judged against standards formulated from the results of
many individuals, so a degree of discrepancy could be
expected. Second, only 1 objective measure of ocular and
oral dryness was used. USF is the test of choice for
assessing salivary secretion (20); however, variations of
methods exist for measuring ocular dryness. While the
Schirmer I test is a valid assessment, issues regarding
reproducibility and sensitivity have been reported (47),
and its use without anesthesia (as in the present study)
includes both basal and reflex lachrymal secretion (48),
which may exaggerate the severity of objective ocular dry-
ness in those with progressive corneal desensitization.
Categories of objective symptoms were derived specifi-
cally for this study, in order to calculate the sensitivity
score. While the expert opinion of a consulting rheuma-
tologist was used in developing the categories and
exploratory work using different cutoff scores or different
ways of categorizing patients showed the same pattern of
relationships, the categories used here need further
empirical support and replication in future studies to
determine whether or not they can be operationalized
and used clinically.
Going forward, we advocate the use of a measure of
objective-subjective symptom discordance, such as that
outlined here, to facilitate illness stratification to allow for
further research into the reasons behind this. Of particular
interest are the groups with the greatest discordance, i.e.,
patients reporting severe subjective symptoms despite
being at the milder end of the objective symptom distribu-
tion, and those reporting mild subjective symptoms
despite being at the severe end of the objective distribu-
tion. An exploration of potential physical and psychologic
explanations for this phenomenon is warranted. For exam-
ple, is there a difference in pathophysiology that might
contribute to the increased experience of mildly abnormal
objective symptoms, such as tear and saliva composition,
changes in corneal sensitivity, or genetic differences in,
for example, pain sensitivity? Conversely, there is detailed
literature on the psychologic aspects of interoception and
pain perception. Applying some of the methodologies
from this literature to develop our understanding of the
individual differences in the felt experience of physical
symptoms would allow us to explore alternative treatment
options, such as cognitive–behavioral therapy or mindful-
ness for those with lower symptom tolerance/higher sub-
jective symptom distress (49–51).
In conclusion, the study developed a novel method for
determining symptom sensitivity. Discrepancies between
objective measures and subjective symptoms were most
strongly related to pain and fatigue; however, multiple
interrelated psychologic, pathophysiologic, and environ-
mental factors are likely involved. Limitations associated
with accurately measuring dry eyes/mouth both subjec-
tively and objectively may also contribute to the
observed discrepancies. Stratifying patients by symptom
sensitivity for further research will improve our under-
standing of factors that have an impact on distress
caused by symptoms and could open the door to non-
medication-based treatments for a subgroup of patients
with the most sensitivity to symptoms.
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APPENDIX A: MEMBERS OF THE UK PRIMARY
SJ€OGREN’S SYNDROME REGISTRY
Simon J. Bowman, Bhaskar Dasgupta, and W. Fai Ng are UK
Primary Sj€ogren’s Syndrome Registry investigators. The other UK
Primary Sj€ogren’s Syndrome Registry members (as of January 1,
2013) are as follows: Frances Hall (Addenbrooke’s Hospital,
Cambridge); Elalaine C. Bacabac, Robert Moots (Aintree Univer-
sity Hospitals); Kuntal Chakravarty, Shamin Lamabadusuriya
(Barking, Havering, and Redbridge NHS Trust); Michele
Bombardieri, Constantino Pitzalis, Nurhan Sutcliffe (Bart and the
London NHS Trust); Nagui Gendi, Rashidat Adeniba (Basildon
Hospital); John Hamburger, Andrea Richards (Birmingham Den-
tal Hospital); Saaeha Rauz (Birmingham & Midland Eye Centre);
Sue Brailsford (University Hospitals Birmingham); Joanne Logan,
Diarmuid Mulherin (Cannock Chase Hospital); Jacqueline
Andrews, Paul Emery, Alison McManus, Colin Pease (Chapel
Allerton Hospital, Leeds); Alison Booth, Marian Regan (Royal
Derby Hospital); Theodoros Dimitroulas, Lucy Kadiki, Daljit
Kaur, George Kitas (Dudley Group of Hospitals NHS Foundation
Trust); Mark Lloyd, Lisa Moore (Frimley Park Hospital); Esther
Gordon, Cathy Lawson (Harrogate District Foundation Trust
Hospital); Monica Gupta, John Hunter, Lesley Stirton (Gartnavel
General Hospital, Glasgow); Gill Ortiz, Elizabeth Price (Great
Western Hospital); Gavin Clunie, Ginny Rose, Sue Cuckow (Ips-
wich Hospital NHS Trust); Susan Knight, Deborah Symmons,
Beverley Jones (Macclesfield District General Hospital & Arthritis
Research UK Epidemiology Unit, Manchester); Shereen Al-Ali,
Andrew Carr, Katherine Collins, Ian Corbett, Christine Downie,
Suzanne Edgar, Marco Carrozzo, Francisco Figuereido, Heather
Foggo, Ben Hargreaves, Victoria Hindmarsh, Claire Humphreys,
Katherine James, Dennis Lendrem, James Locke, Iain Macleod,
Philip Mawson, Sheryl Mitchell, Philip Stocks, Jessica Tarn
(Newcastle upon Tyne Hospitals NHS Foundation Trust and
Newcastle University); Adrian Jones, Peter Lanyon, Alice Muir
(Nottingham University Hospital); Paula White, Steven Young-
Min (Portsmouth Hospitals NHS Trust); Susan Pugmire,
Saravanan Vadivelu (Queen’s Elizabeth Hospital, Gateshead);
Annie Cooper, Marianne Watkins (Royal Hampshire County
Hospital); Anne Field, Stephen Kaye, Devesh Mewar, Patricia
Medcalf, Pamela Tomlinson, Debbie Whiteside (Royal Liverpool
University Hospital); Neil McHugh, John Pauling, Julie James,
Nike Olaitan (Royal National Hospital for Rheumatic Diseases);
Mohammed Akil, Jayne McDermott, Olivia Godia (Royal Shef-
field Hospital); David Coady, Elizabeth Kidd, Lynne Palmer
(Sunderland Royal Hospital); Bhaskar Dasgupta, Victoria
Katsande, Pamela Long (Southend University Hospital); Charles
Li (Royal Surrey Hospital); Usha Chandra, Kirsten MacKay (Tor-
bay Hospital); Stefano Fedele, Ada Ferenkeh-Koroma, Ian Giles,
David Isenberg, Helena Maconnell, Stephen Porter (University
College Hospital and Eastman Dental Institute); Paul Allcoat,
John McLaren (Whyteman’s Brae Hospital, Kirkcaldy).
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